The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System
Neovasc has received positive guidance from NICE in the UK, supporting the use of the Neovasc Reducer for patients with refractory angina. This is the first therapeutic intervention recommended for stable angina patients who have not responded to other treatments. The recommendation emphasizes the need for informed consent and patient selection by specialized teams. Neovasc's CEO expressed optimism about expanding access to this therapy, which is already CE-marked in the EU, and has the potential to alleviate symptoms for millions affected by refractory angina.
- NICE guidance marks the first therapeutic support for refractory angina patients.
- The Neovasc Reducer is CE-marked in the EU, validating its use for treatment.
- Expanded reimbursement by NICE could enhance accessibility for patients.
- None.
VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance supporting the implantation of the Neovasc Reducer™ (“Reducer”) in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.
NICE’s current guideline on stable angina describes recommendations on managing stable angina that has not responded to treatment. For these stable angina patients who are refractory to treatment, NICE has limited its recommendations to addressing the psychological factors of patients’ pain. Prior to the new guidance supporting coronary sinus reduction, NICE has not supported any therapeutic interventions.
NICE’s recommendation is important, as it supports the very first therapeutic intervention for stable angina patients who have not responded to treatment.
According to the new guidance document, “Coronary sinus narrowing device implantation is indicated for people in whom other treatment options (medical or surgical) have failed or are not possible (refractory angina). The aim is to reduce symptoms and to improve quality of life.”
An independent advisory committee is responsible for making the interventional procedures recommendations. The committee includes both health professionals and people familiar with the issues that can affect patients and caregivers. The coronary sinus narrowing device was recommended with “Special Arrangements”, which according to NICE, “...is often made when the procedure is considered to be emerging practice in the National Health Service.” It places emphasis on the need for informed consent and suggests that clinicians using these procedures should collect data and enter them into a national database. The guidance further recommends that patient selection should be done by a multidisciplinary team and the procedure should only be done in centers by interventional cardiologists with specific training in the technique.
Prof. Jonathan Hill, MD, Consultant Interventional Cardiologist at Royal Brompton & Harefield NHS Foundation Trust, London, U.K., commented, “The NICE committee that evaluated the coronary sinus narrowing device extensively reviewed the available clinical data regarding the Reducer device. Today’s guidance document is good news for patients in the United Kingdom suffering from refractory angina that haven’t had treatment options supported by NICE guidance.”
“Today’s NICE guidance offers new hope for patients,” stated Fred Colen, President and Chief Executive Officer of Neovasc. “Health authorities around the world recognize the expertise of NICE. We’re gratified that the committee chose to evaluate the Reducer, and we are pleased with their decision. The new guidance, coupled with the expanded reimbursement granted by NICE earlier this year, will help to expand access to the Reducer therapy for patients that previously had no good options.”
About Reducer
The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.
While the Reducer is not approved for commercial use in the United States, the FDA granted Breakthrough Device designation to the Reducer in October 2018. This designation is granted by the FDA in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives.
Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
ICR Westwicke
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the implications from the NICE guidance, the growing incidence of refractory angina and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company's ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company's operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company's expected schedule; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company's common shares (the "Common Shares") may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company's conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company's products; risks relating to health and safety concerns associated with the Company's products and industry; risks relating to the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a "passive foreign investment company"; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; risks relating to the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company's constating documents which could discourage a third-party from making a takeover bid beneficial to the Company's shareholders. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Information Form and in the Management's Discussion and Analysis for the three and six months ended June 30, 2021 (copies of which may be obtained at or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law. www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What did NICE announce regarding Neovasc (NVCN) on November 24, 2021?
How does the NICE guidance impact Neovasc (NVCN) stock?
Why is the NICE recommendation important for Neovasc (NVCN)?
What is the Neovasc Reducer approved for in Europe?
